

## FRANCESCO PASSIGLIA, MD

### EDUCATION AND WORKING HISTORY

Dates	2005 - 2011
Name of organization :	Palermo University, Italy
Faculty	Medicine and Surgery
Title of qualification	MD, Medical Doctor
Dates	2012 - 2017
Name of organization :	Palermo University Hospital, Italy
Faculty	Specialization School in Medical Oncology
Title of qualification	Medical Oncologist
Dates	2013 - 2014
Name of organization :	Antwerp University Hospital, Edegem, Belgium
Faculty	Phase I- Early Clinical Trials Unit, Oncology Department
Title of qualification	Investigational Cancer Therapeutics Fellowship Drug Development: Clinical and Experimental Program
Dates	November 2017
Name of organization :	Palermo University Hospital, Italy
Faculty	PhD course in Medical Oncology
Title of qualification	PhD

### PERSONAL SKILLS AND COMPETENCES

Mother Language:	Italian
Other Languages :	English (Good reading, spoken and written)
Informatics:	Good

### MEMBERSHIP PROFESSIONAL/SCIENTIFIC SOCIETIES

- IALSC (International Association for the Study of Lung Cancer)
- ASCO (American Association of Clinical Oncology)
- ESMO (European Society of Medical Oncology)
- AIOM (Italian Association of Medical Oncology)

### SCIENTIFIC EXPERTISE IN CLINICAL TRIALS

- Certificate in Good Clinical Practice
- Participation as sub-investigator in several phase II-III trials
- Experience in First in Human Trials

## RESEARCH EXPERIENCES:

- **2013 - 2014:** 1-year research fellowship in Investigational Cancer Therapeutics-Drugs Development, at the Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital. Under the supervision of my tutor, Prof. C. Rolfo, I improved my translational research skills, acquiring experience in phase I - first in human clinical trials and obtaining the certification of Fellowship Program in Drug Development by the Antwerp University
- **2015 – 2017:** translational research in the laboratory of molecular biology - Oncology Department, at Palermo University Hospital, focused on immunotherapy biomarkers in NSCLC.

## SCIENTIFIC AWARDS

- **BEST OF WCLC 2015**, (Bari - ITALY, 14<sup>th</sup> September 2015)
- **IASLC ACADEMY AWARD – WCLC 2017-2018**

## SCIENTIFIC COURSES

- **THORACIC ACADEMY – Italy 2017-2018 (Scientific Secretary)**

## BOOKS AND HANDBOOKS

- **Targeted Therapies for Solid Tumors: A Handbook for Moving Toward New Frontiers in Cancer Treatment (Springer)**  
Editors: Russo Antonio, Rosell Rafael, Rolfo Christian (Eds.)

*Chapter 3: Biomarkers as Prognostic, Predictive, and Surrogate Endpoints*

Passiglia Francesco, Cicero Giuseppe, Castiglia Marta, Bazan Viviana

*Chapter 8: Targeted Therapies for Non-Small Cell Lung Cancer*

Russo Antonio, Rolfo Christian, Passiglia Francesco, Rosell Rafael

- **Liquid biopsy in cancer patients: for the hand lens to investigate tumor evolution (Springer)**

Editors: Russo Antonio, Giordano Antonio, Rolfo Christian (Eds.)

*Chapter 5: Liquid biopsy in Non-Small Cell Lung Cancer (NSCLC)*

Christian Rolfo, Marta Castiglia, Alessandro Perez, Pablo Reclusa, Patrick Pauwels, Laure Sober,

Francesco Passiglia, Antonio Russo

## SCIENTIFIC PUBLICATIONS

- **Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations.**

Fanale D, Iovanna JL, Calvo EL, Berthezene P, Belleau P, Dagorn JC, Ancona C, Catania G, D'Alia P, Galvano A, Gulotta E, Lo Dico S, **Passiglia F**, Bronte G, Midiri M, Lo Re G, Cicero G, Bazan V, Russo A. *Oncology*. 2013;85(5):306-11.

- **Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.**  
Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, **Passiglia F**, Castiglia M, Rizzo S, Vullo FL, Fiorentino E, Van Meerbeeck J, Russo A.  
*Crit Rev Oncol Hematol*. 2014 Feb;89(2):300-13.
- **ALK and crizotinib: after the honeymoon...what else? Resistance mechanisms and new therapies to overcome it.**  
Rolfo C, **Passiglia F**, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, Zwaenepoel K, De Wilde A, Bronte G, Russo A, Van Meerbeeck JP, Van Schil P, Pauwels P.  
*Transl Lung Cancer Res*. 2014 Aug;3(4):250-61.
- **Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.**  
Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, **Passiglia F**, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R.  
*Cancer Treat Rev*. 2014 Sep;40(8):990-1004.
- **The role of targeted therapy for gastrointestinal tumors.**  
Rolfo C, Bronte G, Sortino G, Papadimitriou K, **Passiglia F**, Fiorentino E, Marogy G, Russo A, Peeters M.  
*Expert Rev Gastroenterol Hepatol*. 2014 Nov;8(8):875-85.
- **Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?**  
Rolfo C, **Passiglia F**, Russo A, Pauwels P.  
*Expert Opin Ther Targets*. 2014 Sep;18(9):983-5.
- **Ramucirumab and its use in gastric cancer treatment.**  
Bronte G, Galvano A, Cicero G, **Passiglia F**, Rolfo C, Bazan V, Russo A.  
*Drugs Today (Barc)*. 2014 Sep;50(9):613-21.
- **Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?**  
Rolfo C, Sortino G, Smits E, **Passiglia F**, Bronte G, Castiglia M, Russo A, Santos ES, Janssens A, Pauwels P, Raez L.  
*Expert Rev Anticancer Ther*. 2014 Oct;14(10):1173-87.
- **The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?**  
**Passiglia F**, Van Der Steen N, Raez L, Pauwels P, Gil-Bazo I, Santos E, Santini D, Tesoriere G, Russo A, Bronte G, Zwaenepoel K, Cappuzzo F, Rolfo C.  
*Curr Drug Targets*. 2014;15(14):1284-92.

- **Liquid biopsies in lung cancer: the new ambrosia of researchers.**  
 Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, Zwaenepoel K, Gil-Bazo I, **Passiglia F**, Carreca AP, Taverna S, Vento R, Peeters M, Russo A, Pauwels P.  
 Biochim Biophys Acta. 2014 Dec;1846(2):539-46.
  
- **Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.**  
 Bronte G, Sortino G, **Passiglia F**, Rizzo S, Lo Vullo F, Galvano A, Bazan V, Rolfo C, Russo A.  
 Expert Opin Biol Ther. 2015 Jan;15(1):45-59.
  
- **Improvement in lung cancer outcomes with targeted therapies: an update for family physicians.**  
 Rolfo C, **Passiglia F**, Ostrowski M, Farracho L, Ondřejichová T, Dolcan A, Castiglia M, Remmen R, Papadimitriou K, Pauwels P.  
 J Am Board Fam Med. 2015 Jan-Feb;28(1):124-33.
  
- **Cancer and the microbiome: potential applications as new tumor biomarker.**  
 Shahanavaj K, Gil-Bazo I, Castiglia M, Bronte G, **Passiglia F**, Carreca AP, del Pozo JL, Russo A, Peeters M, Rolfo C.  
 Expert Rev Anticancer Ther. 2015 Mar;15(3):317-30.
  
- **What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis**  
 G Bronte, C Rolfo, **F Passiglia**, S Rizzo, I Gil-Bazo, E Fiorentino, M Cajozzo, JP Van Meerbeeck, C Lequaglie, D Santini, P. Pauwels, A Russo  
 Crit Rev Oncol Hematol. 2015 Sep;95(3):306-17.
  
- **Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?**  
 Bronte G, **Passiglia F**, Galvano A, Russo A.  
 Expert Opin Biol Ther. 2015 Aug 3:1-5.
  
- **New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?**  
 Bronte G, Silvestris N, Castiglia M, Galvano A, **Passiglia F**, Sortino G, Cicero G, Rolfo C, Peeters M, Bazan V, Fanale D, Giordano A, Russo A.  
 Oncotarget. 2015 Jul 22.
  
- **Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?**  
**Passiglia F**, Bronte G, Castiglia M, Listì A, Calò V, Toia F, Cicero G, Fanale D, Rizzo S, Bazan V, Russo A.  
 Expert Opin Biol Ther. 2015 Sep 11:1-14.
  
- **Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?**

Daniele Fanale, Giuseppe Bronte, **Francesco Passiglia**, Valentina Calò, Marta Castiglia, Florinda Di Piazza, Maria Teresa Catarella and Nadia Barraco, Antonina Cangemi, Lavinia Insalaco, Angela Listi, Rossella Maragliano, Daniela Massihnia, Alessandro Perez, Francesca Toia, Giuseppe Cicero, Viviana Bazan.

Anal Cell Pathol (Amst). 2015;2015:690916.

- **Entrectinib, a potent new TRK, ROS1, and ALK inhibitor: new therapeutic opportunity not only for Non Small Cell Lung Cancer**  
Christian Rolfo, Rossana Ruiz, Elisa Giovannetti, Ignacio Gil-Bazo, Antonio Russo, Francesco Passiglia, Marco Giallombardo, Marc Peeters and Luis Raez.  
Expert Opin Investig Drugs. 2015;24(11):1493-500.
- **Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis**  
**Francesco Passiglia**, Giuseppe Bronte, Viviana Bazan, Antonio Galvano, Bruno Vincenzi, Antonio Russo.  
Crit Rev Oncol Hematol. 2016 Mar;99:150-7
- **The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer.**  
**Passiglia F**, Caparica R, Giovannetti E, Giallombardo M, Listi A, Diana P, Cirrincione G, Caglevic C, Raez LE, Russo A, Rolfo C.  
Expert Opin Investig Drugs. 2016 Apr;25(4):385-92.
- **PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis**  
**Francesco Passiglia**, Giuseppe Bronte, Viviana Bazan, Sergio Rizzo, Antonio Galvano, Angela Listi, Giuseppe Cicero, Christian Rolfo, Daniele Santini, Antonio Russo  
Oncotarget. 2016 Feb 22.
- **The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.**  
Bronte G, Franchina T, Alù M, Sortino G, Celesia C, **Passiglia F**, Savio G, Laudani A, Russo A, Picone A, Rizzo S, De Tursi M, Gambale E, Bazan V, Natoli C, Blasi L, Adamo V, Russo A.  
Oncotarget. 2016 Mar 16.
- **Nintedanib in NSCLC: evidence to date and place in therapy.**  
Bronte G, **Passiglia F**, Galvano A, Barraco N, Listi A, Castiglia M, Rizzo S, Fiorentino E, Bazan V, Russo A.  
Ther Adv Med Oncol. 2016 May;8(3):188-97.
- **Multidisciplinary management of patients with liver metastasis from colorectal cancer.**  
De Greef K, Rolfo C, Russo A, Chapelle T, Bronte G, **Passiglia F**, Coelho A, Papadimitriou K, Peeters M.  
World J Gastroenterol. 2016 Aug 28;22(32):7215-25
- **The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?**  
Bronte G, Incorvaia L, Rizzo S, **Passiglia F**, Galvano A, Rizzo F, Rolfo C, Fanale D, Listi A, Natoli C, Bazan V, Russo A.

Crit Rev Oncol Hematol. 2016 Nov;107:20-32

- **Adding chemotherapy to TKI: can we improve first-line treatment for EGFR-mutated NSCLC patients?**  
**Francesco Passiglia** and Antonio Russo.  
Transl Cancer Res 2016;5(Suppl 7):S1413-S1416.
- **"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.**  
Incorvaia L, **Passiglia F**, Rizzo S, Galvano A, Listi A, Barraco N, Maragliano R, Calò V, Natoli C, Ciaccio M, Bazan V, Russo A.  
Oncotarget. 2016 Dec 31.
- **Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway**  
Laura La Paglia, Angela Listi, Stefano Caruso, Valeria Amodeo, **Francesco Passiglia**, Viviana Bazan, and Daniele Fanale.  
PPAR Res. 2017;2017:8187235.
- **Overcoming Resistance to EGFR-TKIs: The Potential Role of Third-Generation Inhibitors**  
**Francesco Passiglia** and Antonio Russo  
J Cancer Clin Trials 2017; 2: 124.
- **Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.**  
Corrales L, Nogueira A, **Passiglia F**, Listi A, Caglevic C, Giallombardo M, Raez L, Santos E, Rolfo C  
Front Med (Lausanne). 2017 Feb 28;4:13.
- **Immune-Checkpoint Inhibitors in NSCLC: Moving to the First-Line**  
**Francesco Passiglia**, Sergio Rizzo and Antonio Russo  
J Dev Drugs 2017; 6: e150.
- **EGFR inhibition in NSCLC: New findings.... and opened questions?**  
**Passiglia F**, Listi A, Castiglia M, Perez A, Rizzo S, Bazan V, Russo A.  
Crit Rev Oncol Hematol. 2017 Apr;112:126-135
- **Upfront Radiation or EGFR-TKI: Which is the best approach for EGFR-mutated NSCLC patients with brain metastasis ?**  
**Francesco Passiglia** and Christian Rolfo  
Transl Cancer Res 2017; 6(Suppl 3): S533-536
- **Immune Checkpoint inhibitors in Lung Cancer: The Holy Grail has not yet been found...**  
Satheesh Thungappa, Jose Ferri, Christian Caglevic, **Francesco Passiglia**, Luis Raez, Christian Rolfo.  
ESMO Open 2017; 0:e000162
- **Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab, and atezolizumab.**  
**Passiglia F**, Galvano A, Rizzo S, Incorporvaia L, Listi A, Bazan V, Russo A.

Int J Cancer. 2017 Oct 28. doi: 10.1002/ijc.31136.

- **The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials.**

Rizzo S, Galvano A, Pantano F, Iuliani M, Vincenzi B, **Passiglia F**, Spoto S, Tonini G, Bazan V, Russo A, Santini D.

Crit Rev Oncol Hematol. 2017 Oct 16. pii: S1040-8428(17)30225-1.

## **ABSTRACTS ACCEPTED AT SCIENTIFIC AND PROFESSIONAL MEETINGS**

### **Abstracts accepted for 2014 Meetings:**

- **Molecular analysis of BRAF gene and PTEN gene expression in metastatic colorectal cancer patients: feasibility study**  
The 105 th Annual Meeting of the American Association for Cancer Research will be held April 5-9, 2014, in San Diego, California
- **A literature-based meta-analysis about the comparison between platinum-based doublet and single agent chemotherapy in PS 2 NSCLC patients**  
European Lung Cancer Conference (ELCC) March 2014 Geneva.
- **Liquid biopsies in Non Small-Cell Lung Cancer: from the preclinical towards the clinical application**  
EORTC Pharmacology & Molecular Mechanisms Group - Münster, Germany 12 February 2014 - 15 February 2014

### **Abstracts accepted for 2015 Meetings:**

- **The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: findings from a retrospective analysis.**  
ASCO Abstract #150446 - 2015 ASCO Annual Meeting (May 29 - June 2, 2015)
- **PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis**  
IASLC 16<sup>th</sup> World Conference on Lung Cancer, September 6-9, 2015

### **Abstracts accepted for 2016 Meetings:**

- **KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis**  
ASCO Abstract 3565 –2016 ASCO Annual Meeting (June 4 - 6, 2016)

- **The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis**  
AIOM Abstract D08 – AIOM Annual Meeting (28-30 October 2016).

**Abstracts accepted for 2017 Meetings:**

- **Metastatic site location may influence the diagnostic accuracy of plasma EGFR-mutation testing in NSCLC: a pooled analysis**  
European Lung Cancer Conference (ELCC) 6-9 May 2017, Geneve
- **Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab**  
European Lung Cancer Conference (ELCC) 6-9 May 2017, Geneve
- **Numerical, dimensional or mixed progression disease to imatinib as prognostic factor in patients with metastatic GIST**  
ASCO Abstract 11040 –2017 ASCO Annual Meeting (3-7 June 2017)
- **Predictive factors of response to sunitinib in metastatic gastrointestinal stromal tumours (mGISTs): a retrospective analysis**  
ESMO Abstract 1516P – ESMO 2017 Congress (8-12 September 2017)